CL2007003041A1 - Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto p - Google Patents
Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto pInfo
- Publication number
- CL2007003041A1 CL2007003041A1 CL200703041A CL2007003041A CL2007003041A1 CL 2007003041 A1 CL2007003041 A1 CL 2007003041A1 CL 200703041 A CL200703041 A CL 200703041A CL 2007003041 A CL2007003041 A CL 2007003041A CL 2007003041 A1 CL2007003041 A1 CL 2007003041A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- inhibiting
- mitogen
- understands
- kit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86256906P | 2006-10-23 | 2006-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003041A1 true CL2007003041A1 (es) | 2008-03-24 |
Family
ID=39954277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200703041A CL2007003041A1 (es) | 2006-10-23 | 2007-10-23 | Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto p |
Country Status (25)
Country | Link |
---|---|
US (4) | US7696218B2 (es) |
EP (1) | EP2091941B1 (es) |
JP (1) | JP5249939B2 (es) |
KR (1) | KR20090071666A (es) |
CN (1) | CN101563338A (es) |
AR (1) | AR063357A1 (es) |
AU (1) | AU2007353385A1 (es) |
BR (1) | BRPI0717374A2 (es) |
CA (1) | CA2667447A1 (es) |
CL (1) | CL2007003041A1 (es) |
CO (1) | CO6180442A2 (es) |
CR (1) | CR10818A (es) |
DO (1) | DOP2009000089A (es) |
EA (1) | EA200970407A1 (es) |
EC (1) | ECSP099354A (es) |
IL (1) | IL198254A0 (es) |
MA (1) | MA30889B1 (es) |
MX (1) | MX2009004269A (es) |
NO (1) | NO20091999L (es) |
NZ (1) | NZ577047A (es) |
PE (1) | PE20081468A1 (es) |
TN (1) | TN2009000151A1 (es) |
TW (1) | TW200831100A (es) |
WO (1) | WO2008140553A2 (es) |
ZA (1) | ZA200903274B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5249939B2 (ja) * | 2006-10-23 | 2013-07-31 | 武田薬品工業株式会社 | Mapk/erkキナーゼ阻害剤 |
JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
US8022057B2 (en) * | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
WO2010021752A1 (en) | 2008-08-21 | 2010-02-25 | Alvine Pharmaceuticals, Inc. | Formulation for oral administration of proteins |
WO2013151877A1 (en) * | 2012-04-03 | 2013-10-10 | Bristol-Myers Squibb Company | Pyrimidinedione carboxamide inhibitors of endothelial lipase |
KR20150119012A (ko) * | 2013-02-08 | 2015-10-23 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Erk 억제제 및 이의 용도 |
DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
DE102015117207A1 (de) | 2015-10-08 | 2017-04-13 | Silas Mehmet Aslan | Verfahren zur Herstellung von polythiophenhaltigen Fluiden |
IL259810A (en) | 2018-06-04 | 2018-07-31 | Yeda Res & Dev | Mitogen-activated protein kinase kinase 7 inhibitors |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58152890A (ja) * | 1982-03-08 | 1983-09-10 | Takeda Chem Ind Ltd | イソキサゾロピリミジン誘導体 |
WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
DE69836378T2 (de) | 1997-07-01 | 2007-10-11 | Warner-Lambert Co. Llc | Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren |
CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
AU5316900A (en) * | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
SI1301472T1 (sl) | 2000-07-19 | 2014-05-30 | Warner-Lambert Company Llc | Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin |
WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
CA2587178A1 (en) | 2004-11-24 | 2006-06-01 | Laboratoires Serono S.A. | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
US20060223807A1 (en) * | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
AR055057A1 (es) | 2005-05-18 | 2007-08-01 | Array Biopharma Inc | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. |
JP5249939B2 (ja) * | 2006-10-23 | 2013-07-31 | 武田薬品工業株式会社 | Mapk/erkキナーゼ阻害剤 |
JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
US8022057B2 (en) | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
US20090246198A1 (en) * | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
-
2007
- 2007-10-22 JP JP2009534802A patent/JP5249939B2/ja active Active
- 2007-10-22 NZ NZ577047A patent/NZ577047A/en not_active IP Right Cessation
- 2007-10-22 WO PCT/US2007/082138 patent/WO2008140553A2/en active Application Filing
- 2007-10-22 EA EA200970407A patent/EA200970407A1/ru unknown
- 2007-10-22 ZA ZA200903274A patent/ZA200903274B/xx unknown
- 2007-10-22 US US11/876,635 patent/US7696218B2/en active Active
- 2007-10-22 US US12/446,974 patent/US20100204471A1/en not_active Abandoned
- 2007-10-22 CA CA002667447A patent/CA2667447A1/en not_active Abandoned
- 2007-10-22 MX MX2009004269A patent/MX2009004269A/es active IP Right Grant
- 2007-10-22 KR KR1020097010570A patent/KR20090071666A/ko not_active Application Discontinuation
- 2007-10-22 EP EP07874225A patent/EP2091941B1/en active Active
- 2007-10-22 CN CNA2007800471578A patent/CN101563338A/zh active Pending
- 2007-10-22 AU AU2007353385A patent/AU2007353385A1/en not_active Abandoned
- 2007-10-22 BR BRPI0717374-1A patent/BRPI0717374A2/pt not_active IP Right Cessation
- 2007-10-23 CL CL200703041A patent/CL2007003041A1/es unknown
- 2007-10-23 PE PE2007001430A patent/PE20081468A1/es not_active Application Discontinuation
- 2007-10-23 TW TW096139723A patent/TW200831100A/zh unknown
- 2007-10-23 AR ARP070104689A patent/AR063357A1/es not_active Application Discontinuation
-
2009
- 2009-04-21 IL IL198254A patent/IL198254A0/en unknown
- 2009-04-22 TN TNP2009000151A patent/TN2009000151A1/fr unknown
- 2009-04-23 DO DO2009000089A patent/DOP2009000089A/es unknown
- 2009-05-13 MA MA31870A patent/MA30889B1/fr unknown
- 2009-05-21 EC EC2009009354A patent/ECSP099354A/es unknown
- 2009-05-21 CR CR10818A patent/CR10818A/es not_active Application Discontinuation
- 2009-05-22 CO CO09053035A patent/CO6180442A2/es not_active Application Discontinuation
- 2009-05-22 NO NO20091999A patent/NO20091999L/no not_active Application Discontinuation
-
2010
- 2010-01-05 US US12/652,570 patent/US7943626B2/en active Active
-
2011
- 2011-04-07 US US13/082,259 patent/US8088783B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003041A1 (es) | Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto p | |
CL2007003212A1 (es) | Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
CL2008000094A1 (es) | Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion. | |
BRPI0809977A2 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
CL2007001325A1 (es) | Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades. | |
CL2007001759A1 (es) | Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes. | |
CL2015000148A1 (es) | Inmunoglobulina g variante porque comprende dos o mas sustituciones de aminoácidos; composición farmacéutica y kit que comprenden dicha inmunolobulina; uso de dicha inmunoglobulina para tratar tumor | |
CU23871B1 (es) | Composiciones y métodos de uso para anticuerpos de dickkopf-1 | |
CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
ECSP088800A (es) | Formulaciones de inhibidores de DPP IV | |
CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2007003470A1 (es) | Compuestos derivados de urea; composicion farmaceutica que comprende a dichos compuestos; y su uso como antibacterianos. | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
CL2008001273A1 (es) | Compuestos derivados de heterociclos, inhibidores de proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la inflamacion, enfermedad cardiovascular, asma | |
GT200900010A (es) | Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) | |
CL2007002021A1 (es) | Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias. | |
BRPI0815079A2 (pt) | Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto | |
CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
CL2008000784A1 (es) | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co | |
EP1970076A4 (en) | PHARMACEUTICAL COMPOSITION FOR APPLYING TO A NAIL | |
CL2007003232A1 (es) | Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas. | |
ATE453384T1 (de) | Neue dosierformulierung | |
CL2008002041A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad. |